Organon's fourth quarter of 2025 saw total revenue decline by 5% to $1.507 billion, with a reported net loss of $205 million, or $0.79 per diluted share, primarily due to a $301 million goodwill impairment. Adjusted EBITDA decreased by 15% to $383 million.

Organon delivered modest revenue growth in Q3 2025, with strong biosimilars performance and disciplined cost management supporting a solid adjusted EBITDA margin of 32.3%.

Organon's second quarter 2025 revenue was $1.594 billion, a 1% decrease from the prior year. Net income significantly declined by 26% to $145 million, with diluted EPS at $0.56. Non-GAAP Adjusted diluted EPS was $1.00, an 11% decrease. The company made progress on debt reduction and affirmed its Adjusted EBITDA margin guidance.

Organon's first quarter 2025 results showed a decline in revenue and net income compared to the prior year, primarily due to competitive pressures and loss of exclusivity for certain products. Despite this, the company affirmed its full-year 2025 financial guidance, driven by strong performance in key growth drivers like Nexplanon and Vtama, and reset its dividend payout to prioritize deleveraging.

Organon's Q4 2024 revenue remained stable at $1.592 billion, with growth in Established Brands offsetting declines in Biosimilars. Net income fell significantly due to a one-time tax benefit in Q4 2023.

Organon reported a 4% increase in total revenue to $1.582 billion for the third quarter of 2024. Growth was primarily driven by Women's Health and Biosimilars segments. The company maintained disciplined operating costs, contributing to Adjusted EBITDA growth and progress towards achieving $1 billion in free cash flow for the full year.

Organon reported second-quarter revenue of $1.607 billion, flat year-over-year on an as-reported basis but up 2% ex-FX. Women's Health and Biosimilars showed growth, while Established Brands declined slightly. Net income was $195 million, or $0.75 per diluted share. The company is tracking well to its 2024 objectives.

Organon reported a revenue increase of 5% on an as-reported basis and 7% ex-FX, with Women's Health and Biosimilars showing strong growth. The company remains confident in delivering its third year of revenue growth on a constant currency basis and full-year non-GAAP Adjusted EBITDA margins in line with last year, or better.

Organon reported an 8% increase in total revenue to $1,598 million for Q4 2023. The company's growth was primarily fueled by strong performances in Women's Health and Biosimilars segments. Net income increased significantly to $546 million, and adjusted EBITDA margin improved to 28.1%.

Organon reported a slight decrease in revenue for Q3 2023, with Women's Health declining but Biosimilars and Established Brands showing growth. Profitability margins decreased due to foreign exchange, inflation, and product mix. The company narrowed and lowered its full-year revenue guidance.

Organon reported a 1% increase in total revenue to $1,608 million for the second quarter of 2023, or a 4% increase excluding the impact of foreign currency. Women's Health and Biosimilars franchises grew 10% and 15% ex-FX, respectively, while Established Brands remained stable. Net income was $242 million, or $0.95 per diluted share, compared to $234 million, or $0.92 per diluted share, in the second quarter of 2022.

Organon reported a 2% decrease in total revenue as-reported, but a 3% increase excluding the impact of foreign currency, reaching $1,538 million. The company experienced growth in Women's Health and Biosimilars revenues, while Established Brands showed resilience. Net income was $177 million, or $0.69 per diluted share, and non-GAAP adjusted net income was $276 million, or $1.08 per diluted share.

Organon reported a decrease in revenue of 7% as-reported but an increase of 1% ex-FX for Q4 2022. Women's Health and Biosimilars revenue increased, while Established Brands revenue declined. Net income was $108 million, or $0.42 per diluted share, and non-GAAP adjusted net income was $208 million, or $0.81 per diluted share.

Organon reported a 4% decrease in total net revenues as-reported, but a 3% increase excluding the impact of foreign currency. Women's Health grew 19% as-reported and 23% ex-FX. Net income from continuing operations was $227 million, or $0.89 per diluted share. Non-GAAP Adjusted net income from continuing operations was $337 million, or $1.32 per diluted share.

Organon reported a decrease of 1% in total net revenues as-reported, but an increase of 5% excluding the impact of foreign currency compared to Q2 2021. The company saw growth in Biosimilars revenue, and its Established Brands franchise performed well. Organon is updating its full year 2022 guidance ranges and now expects revenue between $6.1 billion and $6.3 billion.

Organon reported a solid start to the year with a 4% increase in total net revenue, reaching $1,567 million. The company saw growth in Biosimilars and Established Brands, while Women's Health experienced a slight decline. Adjusted EBITDA margin improved to 41.3%.

Organon reported a total net revenue of $1,604 million for Q4 2021, a decrease of 1% compared to Q4 2020. Strong sales for Nexplanon and growth in biosimilars were offset by declines in Established Brands and supply sales to Merck and other third parties. Net income from continuing operations for the fourth quarter of 2021 was $202 million, or $0.79 per diluted share, compared with $376 million, or $1.48 per diluted share, in the fourth quarter of 2020.